Amydis Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
12
- Latest Deal Type
-
2ndary - Private
- Investors
-
9
Amydis General Information
Description
Developer of a new class of diagnostic compounds designed for the early detection and treatment of neurodegenerative diseases. The company develops novel, patent-protected small molecule ocular tracers, which enable direct visualization of retinal disease-related molecular changes in the eye, enabling healthcare professionals to identify disorders that involve the presence of amyloid proteins for targeting the detection of early-stage Alzheimer's and other amyloid-associated diseases.
Contact Information
Website
www.amydis.comCorporate Office
- 1801 Century Park East
- Suite 2400
- Los Angeles, CA 90067
- United States
Corporate Office
- 1801 Century Park East
- Suite 2400
- Los Angeles, CA 90067
- United States
Amydis Timeline
Amydis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 17. Secondary Transaction - Private | 01-Apr-2026 | Completed | Clinical Trials - General | |||
| 16. Grant | 11-Mar-2026 | Completed | Clinical Trials - General | |||
| 15. Later Stage VC | 18-Dec-2023 | Completed | Clinical Trials - General | |||
| 14. Grant | 14-Nov-2023 | Completed | Clinical Trials - General | |||
| 13. Later Stage VC (Series A2) | 29-Dec-2022 | Completed | Clinical Trials - General | |||
| 12. Grant | 27-Oct-2022 | Completed | Clinical Trials - General | |||
| 11. Later Stage VC (Series A) | 21-Apr-2022 | Completed | Clinical Trials - General | |||
| 10. Grant | 23-Sep-2021 | Completed | Clinical Trials - General | |||
| 9. Grant | 01-Sep-2021 | $492K | Completed | Clinical Trials - General | ||
| 8. Grant | 10-Aug-2021 | $6.5M | Completed | Clinical Trials - General |
Amydis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Amydis Comparisons
Industry
Financing
Details
Amydis Competitors (14)
One of Amydis’s 14 competitors is Ona Therapeutics, a Venture Capital-Backed company based in Barcelona, Spain.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ona Therapeutics | Venture Capital-Backed | Barcelona, Spain | ||||
| Volastra | Venture Capital-Backed | New York, NY | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Gesynta Pharma | Venture Capital-Backed | Stockholm, Sweden | ||||
| Cardurion | Venture Capital-Backed | Burlington, MA |
Amydis Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Amydis Patents
Amydis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024388718-A1 | Amino acid derivatives for detecting neurological disorders | Pending | 27-Nov-2023 | ||
| EP-4816351-A1 | Amino acid derivatives for detecting neurological disorders | Pending | 27-Nov-2023 | ||
| US-20260327196-A1 | Amino acid derivatives for detecting neurological disorders | Pending | 27-Nov-2023 | ||
| WO-2025117551-A1 | Amino acid derivatives for detecting neurological disorders | Inactive | 27-Nov-2023 | ||
| AU-2024209695-A1 | Amyloid targeting agents | Pending | 18-Jan-2023 | C07D241/04 |
Amydis Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Amydis Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Stead Impact Ventures and Foundation | Impact Investing | Minority | ||
| Michael J. Fox Foundation | Limited Partner | |||
| U.S. Department of Health and Human Services | Government | |||
| National Institutes of Neurological Disorders and Stroke | Government | |||
| National Institutes of Health | Government |
Amydis FAQs
-
When was Amydis founded?
Amydis was founded in 2013.
-
Where is Amydis headquartered?
Amydis is headquartered in Los Angeles, CA.
-
What is the size of Amydis?
Amydis has 12 total employees.
-
What industry is Amydis in?
Amydis’s primary industry is Biotechnology.
-
Is Amydis a private or public company?
Amydis is a Private company.
-
What is Amydis’s current revenue?
The current revenue for Amydis is .
-
How much funding has Amydis raised over time?
Amydis has raised $14.7M.
-
Who are Amydis’s investors?
Stead Impact Ventures and Foundation, Michael J. Fox Foundation, U.S. Department of Health and Human Services, National Institutes of Neurological Disorders and Stroke, and National Institutes of Health are 5 of 9 investors who have invested in Amydis.
-
Who are Amydis’s competitors?
Ona Therapeutics, Volastra, Sangamo Therapeutics, Gesynta Pharma, and Cardurion are some of the 14 competitors of Amydis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
